Two Hedge Funds Poised to Benefit From a SPAC Deal Worth $1.6 Billion
Sarissa and Perceptive stands to benefit from Pear Therapeutics’ merger with Pritzker-backed blank check company.
Stephen TaubJune 22, 2021
Alexander Denner, CIO of Sarissa Capital Management
(Andrew Harrer/Bloomberg)
The IPO market for new blank check companies may have all but dried up for some time.But existing SPACs continue to make deals. And two hedge fund firms figure to be significant beneficiaries in the latest announced merger. Thimble Point Acquisition Corp., whose management team
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.